261 related articles for article (PubMed ID: 23440295)
1. DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma.
Koomoa DL; Geerts D; Lange I; Koster J; Pegg AE; Feith DJ; Bachmann AS
Int J Oncol; 2013 Apr; 42(4):1219-28. PubMed ID: 23440295
[TBL] [Abstract][Full Text] [Related]
2. Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma.
Koomoa DL; Yco LP; Borsics T; Wallick CJ; Bachmann AS
Cancer Res; 2008 Dec; 68(23):9825-31. PubMed ID: 19047162
[TBL] [Abstract][Full Text] [Related]
3. Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells.
Wallick CJ; Gamper I; Thorne M; Feith DJ; Takasaki KY; Wilson SM; Seki JA; Pegg AE; Byus CV; Bachmann AS
Oncogene; 2005 Aug; 24(36):5606-18. PubMed ID: 16007177
[TBL] [Abstract][Full Text] [Related]
4. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.
Rounbehler RJ; Li W; Hall MA; Yang C; Fallahi M; Cleveland JL
Cancer Res; 2009 Jan; 69(2):547-53. PubMed ID: 19147568
[TBL] [Abstract][Full Text] [Related]
5. Synergistic drug combination GC7/DFMO suppresses hypusine/spermidine-dependent eIF5A activation and induces apoptotic cell death in neuroblastoma.
Schultz CR; Geerts D; Mooney M; El-Khawaja R; Koster J; Bachmann AS
Biochem J; 2018 Jan; 475(2):531-545. PubMed ID: 29295892
[TBL] [Abstract][Full Text] [Related]
6. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport.
Samal K; Zhao P; Kendzicky A; Yco LP; McClung H; Gerner E; Burns M; Bachmann AS; Sholler G
Int J Cancer; 2013 Sep; 133(6):1323-33. PubMed ID: 23457004
[TBL] [Abstract][Full Text] [Related]
7. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.
Hogarty MD; Norris MD; Davis K; Liu X; Evageliou NF; Hayes CS; Pawel B; Guo R; Zhao H; Sekyere E; Keating J; Thomas W; Cheng NC; Murray J; Smith J; Sutton R; Venn N; London WB; Buxton A; Gilmour SK; Marshall GM; Haber M
Cancer Res; 2008 Dec; 68(23):9735-45. PubMed ID: 19047152
[TBL] [Abstract][Full Text] [Related]
8. Expression of P27(KIP1) is prognostic and independent of MYCN amplification in human neuroblastoma.
Bergmann E; Wanzel M; Weber A; Shin I; Christiansen H; Eilers M
Int J Cancer; 2001 May; 95(3):176-83. PubMed ID: 11307151
[TBL] [Abstract][Full Text] [Related]
9. Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma.
Schultz CR; Swanson MA; Dowling TC; Bachmann AS
Cancer Chemother Pharmacol; 2021 Oct; 88(4):607-617. PubMed ID: 34129075
[TBL] [Abstract][Full Text] [Related]
10. A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.
Saulnier Sholler GL; Gerner EW; Bergendahl G; MacArthur RB; VanderWerff A; Ashikaga T; Bond JP; Ferguson W; Roberts W; Wada RK; Eslin D; Kraveka JM; Kaplan J; Mitchell D; Parikh NS; Neville K; Sender L; Higgins T; Kawakita M; Hiramatsu K; Moriya SS; Bachmann AS
PLoS One; 2015; 10(5):e0127246. PubMed ID: 26018967
[TBL] [Abstract][Full Text] [Related]
11. The inhibition of activated hepatic stellate cells proliferation by arctigenin through G0/G1 phase cell cycle arrest: persistent p27(Kip1) induction by interfering with PI3K/Akt/FOXO3a signaling pathway.
Li A; Wang J; Wu M; Zhang X; Zhang H
Eur J Pharmacol; 2015 Jan; 747():71-87. PubMed ID: 25498792
[TBL] [Abstract][Full Text] [Related]
12. Suppression of centrosome amplification after DNA damage depends on p27 accumulation.
Sugihara E; Kanai M; Saito S; Nitta T; Toyoshima H; Nakayama K; Nakayama KI; Fukasawa K; Schwab M; Saya H; Miwa M
Cancer Res; 2006 Apr; 66(8):4020-9. PubMed ID: 16618721
[TBL] [Abstract][Full Text] [Related]
13. YAP promotes the proliferation of neuroblastoma cells through decreasing the nuclear location of p27
Shen X; Xu X; Xie C; Liu H; Yang D; Zhang J; Wu Q; Feng W; Wang L; Du L; Xuan L; Meng C; Zhang H; Wang W; Wang Y; Xie T; Huang Z
Cell Prolif; 2020 Feb; 53(2):e12734. PubMed ID: 31863533
[TBL] [Abstract][Full Text] [Related]
14. Targeting ornithine decarboxylase reverses the LIN28/Let-7 axis and inhibits glycolytic metabolism in neuroblastoma.
Lozier AM; Rich ME; Grawe AP; Peck AS; Zhao P; Chang AT; Bond JP; Sholler GS
Oncotarget; 2015 Jan; 6(1):196-206. PubMed ID: 25415050
[TBL] [Abstract][Full Text] [Related]
15. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation.
Nilsson JA; Keller UB; Baudino TA; Yang C; Norton S; Old JA; Nilsson LM; Neale G; Kramer DL; Porter CW; Cleveland JL
Cancer Cell; 2005 May; 7(5):433-44. PubMed ID: 15894264
[TBL] [Abstract][Full Text] [Related]
16. Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma.
Woo CW; Tan F; Cassano H; Lee J; Lee KC; Thiele CJ
Pediatr Blood Cancer; 2008 Feb; 50(2):208-12. PubMed ID: 17420990
[TBL] [Abstract][Full Text] [Related]
17. The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification.
Geerts D; Koster J; Albert D; Koomoa DL; Feith DJ; Pegg AE; Volckmann R; Caron H; Versteeg R; Bachmann AS
Int J Cancer; 2010 May; 126(9):2012-24. PubMed ID: 19960435
[TBL] [Abstract][Full Text] [Related]
18. PRAF2 stimulates cell proliferation and migration and predicts poor prognosis in neuroblastoma.
Yco LP; Geerts D; Koster J; Bachmann AS
Int J Oncol; 2013 Apr; 42(4):1408-16. PubMed ID: 23440329
[TBL] [Abstract][Full Text] [Related]
19. Negative cell cycle regulator 14-3-3sigma stabilizes p27 Kip1 by inhibiting the activity of PKB/Akt.
Yang H; Zhang Y; Zhao R; Wen YY; Fournier K; Wu HB; Yang HY; Diaz J; Laronga C; Lee MH
Oncogene; 2006 Aug; 25(33):4585-94. PubMed ID: 16532026
[TBL] [Abstract][Full Text] [Related]
20. Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling.
Mohammed A; Janakiram NB; Madka V; Ritchie RL; Brewer M; Biddick L; Patlolla JM; Sadeghi M; Lightfoot S; Steele VE; Rao CV
Cancer Prev Res (Phila); 2014 Dec; 7(12):1198-209. PubMed ID: 25248858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]